Why an FDA decision on Stealth’s Barth drug could ripple through the rare disease field
Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could carry broader consequences.
Previous Post
Rate Reality Check: How Capital Women’s Care Stacks Up Against the Competition (Part 2) – The Health Care Blog
Next Post
Chernobyl Tourists Sit On Radioactive Claw As They Pose For Photo: Were They In Fatal Danger?
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago